Radioimmunotherapy (RIT)

Radio immunotherapy (RIT) is a combination of radiation therapy and immunotherapy used to treat non-Hodgkin B-cell lymphoma and other types of cancer. RIT uses engineered monoclonal antibodies paired with radioactive materials called radiotracers. When injected into the patient’s bloodstream, they bind to cancer cells and deliver a high dose of radiation directly to the tumor. In RIT, a monoclonal antibody is paired with a radioactive material, or radiotracer. When injected into the patient’s bloodstream, the radiation-linked monoclonal antibody, or agent, travels to and binds to cancer cells, allowing a high dose of radiation to be delivered directly to the tumor.

 

    Related Conference of Radioimmunotherapy (RIT)

    April 22-23, 2019

    Global Summit on Radiation Therapy & Targeted Tumors

    Vancouver, Canada
    June 12-13, 2019

    22nd Canada Meetings on Radiology & Novel Cancer Therapies

    Montreal, Quebec, Canada

    Radioimmunotherapy (RIT) Conference Speakers

    Recommended Sessions

    Related Journals

    Are you interested in